NCT04891718View on ClinicalTrials.gov

CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia

EARLY_PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 15, 2021

Primary Completion Date

June 5, 2022

Study Completion Date

June 5, 2022

Conditions
Solid Tumour
Interventions
BIOLOGICAL

MVC-101

Intratumoural microdose injection by the CIVO device.

BIOLOGICAL

Nivolumab

Intratumoural microdose injection by the CIVO device.

COMBINATION_PRODUCT

MVC-101 + Nivolumab

Intratumoural microdose injection by the CIVO device.

Trial Locations (3)

2050

Chris O'Brien Lifehouse, Camperdown

2500

Wollongong Hospital, Wollongong

5042

Flinders Medical Centre, Bedford Park

Sponsors

Collaborators (1)

Takeda
All Listed Sponsors
collaborator

Takeda

INDUSTRY

lead

Presage Biosciences

INDUSTRY